SVB Wealth LLC Decreases Stock Position in Becton, Dickinson and Company $BDX

SVB Wealth LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 71.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,426 shares of the medical instruments supplier’s stock after selling 3,519 shares during the period. SVB Wealth LLC’s holdings in Becton, Dickinson and Company were worth $246,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $26,000. Bell Investment Advisors Inc lifted its stake in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 128 shares during the period. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $31,000. Bank of Jackson Hole Trust grew its stake in shares of Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 95 shares during the period. Finally, WPG Advisers LLC purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $36,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $198.44 on Thursday. The business’s fifty day moving average is $188.58 and its 200 day moving average is $184.19. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market capitalization of $56.64 billion, a PE ratio of 34.04, a price-to-earnings-growth ratio of 1.74 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 407 shares of company stock valued at $73,922. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of several research reports. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Jefferies Financial Group increased their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler cut their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada cut their price target on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research note on Friday, November 7th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $204.91.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.